No Data
No Data
Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.
Abnormal movement hits directly | Stocks of innovative drugs concept are on the rise, the 2024 ESMO conference is about to be held, and institutions suggest seizing the Q3 fundamentals turning point and industry catalysis.
Innovative drug concept stocks have risen, as of press time, Beigene (06160) rose 6.97%, to HKD 124.3; Innocare-B (02162) rose 4.92%, to HKD 37.35; Innocare (09969) rose 4.91%, to HKD 5.55.
[Brokerage Focus] China Securities Co., Ltd. maintains a "buy" rating on Remegen (09995), bullish on its commercial development and subsequent clinical advancement of innovative drugs.
China Securities Co., Ltd.'s research report pointed out that Remegen (09995) continued to see strong sales of its core products in the first half of the year, generating revenue of 0.742 billion yuan, achieving a good year-on-year growth. The company's core products, Taitaizipu and Videxitu, cover the areas of immunology and oncology, and the clinical development and commercialization of these two products are steadily progressing. In terms of the innovative pipeline, RC88 announced the latest research results on ovarian cancer at the ASCO conference, showing excellent product efficacy with promising future prospects. Overall, the bank is bullish on the company's commercial development and the subsequent clinical advancement of innovative drugs. The bank points out that the company has established and improved three major innovative drug R&D platforms, and has a strong competitive advantage in the field of innovative drugs.
Remegen (09995.HK) was reduced by Norges Bank by 0.543 million shares
According to the latest equity disclosure data from the Hong Kong Stock Exchange, on August 29, 2024, remegen (09995.HK) was reduced by Norges Bank on the exchange, with an average price of HK$11.9601 per share, reducing its holdings by 0.543 million shares, involving approximately HK$6.4943 million. After the shareholding, Norges Bank's latest shareholding is 9,068,432 shares, and the shareholding ratio has decreased from 5.07% to 4.78%.
RemeGen Co. Enhances Transparency on Incentive Plans
榮昌生物:有關2023年年報的補充公告
No Data
No Data